


LY-2584702 tosylate salt

Chemical Properties

CAS No. :	1082949-68-5
Formula:	C ₂₈ H ₂₇ F ₄ N ₇ O ₃ S
Molecular Weight:	617.62
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	LY-2584702 tosylate salt, a selective ATP-competitive p70S6K inhibitor, is being used in clinical trials for cancer treatment.
Targets(IC50)	S6 Kinase
In vitro	In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. [1] LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus. [2]
In vivo	LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87 mg glioblastoma and HCT116 colon carcinoma xenograft models. [1]

Solubility Information

Solubility	Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 12 mg/mL (19.43 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.62 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6191 mL	8.0956 mL	16.1912 mL
5 mM	0.3238 mL	1.6191 mL	3.2382 mL
10 mM	0.1619 mL	0.8096 mL	1.6191 mL
50 mM	0.0324 mL	0.1619 mL	0.3238 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Tolcher A, et al. *Eur J Cancer*. 2014, 50(5), 867-875.

Tong M, Wong T L, Zhao H, et al Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. *Cell Reports*. 2021, 36(8): 109617.

Shen S, Wu G, Luo W, et al. Leonurine attenuates angiotensin II-induced cardiac injury and dysfunction via inhibiting MAPK and NF- κ B pathway. *Phytomedicine*. 2022: 154519.

Hollebecque A, et al. *Eur J Cancer*. 2014, 50(5), 876-884.

Yang N, Zou C, Luo W, et al. Sclareol attenuates angiotensin II-induced cardiac remodeling and inflammation via inhibiting MAPK signaling. *Phytotherapy Research*. 2022

Lu D, Zhang H, Zhang Y, et al. Secreted MbovP0145 Promotes IL-8 Expression through Its Interactive β -Actin and MAPK Activation and Contributes to Neutrophil Migration. *Pathogens* 2021, 10, 1628. *Pathogens*. 2021

Shen S, Huang Z, Lin L, et al. Tussilagone attenuates atherosclerosis through inhibiting MAPKs-mediated inflammation in macrophages. *International Immunopharmacology*. 2023, 119: 110066.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481